Documentation, Codebook, and Frequencies

Surplus Specimen Laboratory Component: Cystatin C (Surplus Sera)

Survey Years:
2001 to 2002

SAS Export File:
SSCYST_B.XPT

First Published: June 2008
Last revised: N/A
<table>
<thead>
<tr>
<th>Component Description</th>
<th>Cystatin C assayed from stored serum samples from NHANES 2001-2002.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Eligible Sample</th>
<th>All participants aged 60+ with available specimen and a 25% random sample of participants aged 12-59 years. This younger group is supplemented with all individuals with high serum creatinine 1.2 mg/dl in men and &gt;1.0 mg/dl in women) after calibration.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Description of Laboratory Methodology</th>
<th>All assays were conducted using the Dade Behring N Latex Cystatin C assay which is an automated particle-enhanced nephelometric assay (PENIA) run on the Dade Behring Nephelometer II (BNII) (1).</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Laboratory Quality Control and Monitoring</th>
<th>This assay has an intra-assay imprecision of 2.0 - 3.0% coefficient of variation and an inter-assay imprecision of 3.2 - 4.4% coefficient of variation. The assay range is 0.23 - 7.25 mg/dL. A thorough review of different assay methodologies by Newman (2) concluded that it is the most precise automated assay across the clinical concentration range and performed slightly better than the other automated assays in terms of sensitivity and lack of analytical interference.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Data Processing and Editing</th>
<th>All data will be made publicly available.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Analytic Notes</th>
<th>The sub-sample of participants aged 12-59 requires modification of original sampling weights. Weights will be provided by investigators to NCHS and will be adjusted by age, sex, race, and serum creatinine strata to match the original NHANES 2001-2002 design.</th>
</tr>
</thead>
</table>
References


Acknowledgement

This research was supported by NIH grants U01 DK 053869, U01 DK 067651, and U01 DK 35073.

Locator Fields

Title: Cystatin C
Contact Number: 1-866-441-NCHS
Years of Content: 2001-2002
First Published: June 2008
Revised: N/A
Access Constraints: None
Use Constraints: None
Geographic Coverage: National
Subject: Serum Cystatin C
Record Source: NHANES 2001-2002
Survey Methodology: NHANES 2001-2002 is a stratified multistage probability sample of the civilian non-institutionalized population of the U.S.
Medium: NHANES Web site; SAS transport files
Cystatin C (SSCYST_B)

June 2008
### Respondent sequence number

**Target**

B(12 Yrs. to 150 Yrs.)

**SAS Label**

Respondent sequence number

**English Text:** Respondent sequence number.

**English Instructions:**

### Cystatin C (mg/L)

**Target**

B(12 Yrs. to 150 Yrs.)

**SAS Label**

Cystatin C (mg/L)

**English Text:** Cystatin C (mg/L)

**English Instructions:**

<table>
<thead>
<tr>
<th>Code or Value</th>
<th>Description</th>
<th>Count</th>
<th>Cumulative</th>
<th>Skip to Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.43 to 10.7</td>
<td>Range of Values</td>
<td>2924</td>
<td>2924</td>
<td></td>
</tr>
<tr>
<td>.</td>
<td>Missing</td>
<td>8</td>
<td>2932</td>
<td></td>
</tr>
</tbody>
</table>

### Surplus sera cystatin 99-02 weights

**Target**

B(12 Yrs. to 150 Yrs.)

**SAS Label**

Surplus sera cystatin 99-02 weights

**English Text:** Surplus sera cystatin 99-02 weights

**English Instructions:**

<table>
<thead>
<tr>
<th>Code or Value</th>
<th>Description</th>
<th>Count</th>
<th>Cumulative</th>
<th>Skip to Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to 376844.2148</td>
<td>Range of Values</td>
<td>2932</td>
<td>2932</td>
<td></td>
</tr>
<tr>
<td>.</td>
<td>Missing</td>
<td>0</td>
<td>2932</td>
<td></td>
</tr>
</tbody>
</table>